Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms
Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.
Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed.
Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01).
Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Posted 13 Jan, 2020
On 17 Jan, 2020
On 09 Jan, 2020
On 09 Jan, 2020
On 08 Jan, 2020
On 08 Jan, 2020
On 26 Dec, 2019
Received 11 Dec, 2019
Invitations sent on 11 Dec, 2019
On 11 Dec, 2019
On 11 Dec, 2019
Received 11 Dec, 2019
On 01 Dec, 2019
On 30 Nov, 2019
On 30 Nov, 2019
On 27 Nov, 2019
Received 22 Nov, 2019
Received 22 Nov, 2019
On 15 Nov, 2019
Invitations sent on 15 Nov, 2019
On 15 Nov, 2019
On 15 Nov, 2019
On 14 Nov, 2019
On 14 Nov, 2019
Received 09 Oct, 2019
On 09 Oct, 2019
On 28 Sep, 2019
Received 19 Sep, 2019
On 16 Sep, 2019
Invitations sent on 13 Sep, 2019
On 12 Sep, 2019
On 11 Sep, 2019
On 11 Sep, 2019
On 07 Aug, 2019
Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms
Posted 13 Jan, 2020
On 17 Jan, 2020
On 09 Jan, 2020
On 09 Jan, 2020
On 08 Jan, 2020
On 08 Jan, 2020
On 26 Dec, 2019
Received 11 Dec, 2019
Invitations sent on 11 Dec, 2019
On 11 Dec, 2019
On 11 Dec, 2019
Received 11 Dec, 2019
On 01 Dec, 2019
On 30 Nov, 2019
On 30 Nov, 2019
On 27 Nov, 2019
Received 22 Nov, 2019
Received 22 Nov, 2019
On 15 Nov, 2019
Invitations sent on 15 Nov, 2019
On 15 Nov, 2019
On 15 Nov, 2019
On 14 Nov, 2019
On 14 Nov, 2019
Received 09 Oct, 2019
On 09 Oct, 2019
On 28 Sep, 2019
Received 19 Sep, 2019
On 16 Sep, 2019
Invitations sent on 13 Sep, 2019
On 12 Sep, 2019
On 11 Sep, 2019
On 11 Sep, 2019
On 07 Aug, 2019
Background: Parkinson’s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.
Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed.
Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01).
Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.
Figure 1
Figure 2